1 North Wealth Services’s Intellia Therapeutics NTLA Stock Holding History

1 North Wealth Services’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$423	Hold	25	–	–	﹤0.01%	302
2026 Q1	$321	Hold	25	–	–	﹤0.01%	264
2025 Q4	$225	Hold	25	–	–	﹤0.01%	275
2025 Q3	$432	Hold	25	–	–	﹤0.01%	251
2025 Q2	$235	Hold	25	–	–	﹤0.01%	258
2025 Q1	$178	Buy	+25	New	+$253	﹤0.01%	258

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

1 North Wealth Services's NTLA Position: Q2 2026 in Review

1 North Wealth Services held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 25 shares worth $423. The position accounts for ﹤0.01% of the portfolio, ranked #302.

1 North Wealth Services first reported a position in NTLA in Q1 2025 and has held it in 6 quarters since. The position peaked at $432 in Q3 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

1 North Wealth Services held 25 shares of Intellia Therapeutics worth $423 as of Q2 2026.
1 North Wealth Services left its Intellia Therapeutics share count unchanged in Q2 2026.
Intellia Therapeutics made up ﹤0.01% of 1 North Wealth Services's portfolio in Q2 2026, its #302 holding.
1 North Wealth Services first reported a position in Intellia Therapeutics in Q1 2025 and has held it in 6 quarters since.
1 North Wealth Services's Intellia Therapeutics position peaked at $432 in Q3 2025.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on 1 North Wealth Services's 13F filing for Q2 2026, filed 3 Aug 2026.